-
Johnson & Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit
15 Apr 2025 13:28 GMT
… of $2.60.
The pharmaceutical giant reported sales of $21 … was 3.3%. Innovative Medicine sales increased 2.3% or … Results For Psoriasis Oral Pill Study
Growth was driven … oncology, Tremfya (guselkumab) and Simponi/Simponi Aria in immunology, Spravato ( …
-
All the drugs that lose their U.S. patents in 2025
10 Apr 2025 15:49 GMT
… news outlet specializing in pharmaceutical industry analysis and data, … list of globally recognized medications set to lose … as its patent expires.
Simponi / Simponi Aria (Johnson … the treatment of leukemia, is another Novartis drug losing exclusivity …
-
Simponi for ulcerative colitis
28 Mar 2025 22:40 GMT
… (FDA) approves a drug, it tracks and reviews side effects of the medication … reported in clinical trials of Simponi for UC.
During Simponi treatment, your doctor may advise … your doctor or another healthcare professional before taking any medication. The drug …
-
Bio-Thera And Dr. Reddy's Execute Exclusive Commercialization Agreement For BAT2206, A Proposed Stelara® Biosimilar, And BAT2506, A Proposed Simponi® Biosimilar, For Southeast Asia
28 Mar 2025 14:46 GMT
… and BAT2506, a proposed Simponi® biosimilar.
Under the … with access to affordable medicines."
About BAT2206 … other treatments called disease-modifying anti-rheumatic drugs (DMARDs … DRREDDY) is a global pharmaceutical company headquartered in Hyderabad …
-
Dr Reddy's Labs, Bio-Thera collaborate for proposed Stelara, Simponi biosimilar
27 Mar 2025 15:03 GMT
… Biosimilar, and BAT2506, a Proposed Simponi Biosimilar.
Under the agreement, Bio … patients with access to affordable medicines.”
BAT2206 is a proposed biosimilar … enough with other treatments called disease-modifying anti-rheumatic drugs (DMARDs), 3 …
-
Bio-Thera & Dr Reddy’s execute exclusive commercialization pact for biosimilars Stelara & Simponi for Southeast Asia
27 Mar 2025 04:38 GMT
… biosimilar, and BAT2506, a proposed Simponi biosimilar.
Under the agreement, Bio … patients with access to affordable medicines.”
-
Humira Biosimilars Gain Ground as Doctors Adjust And New Therapies Rise
26 Mar 2025 05:10 GMT
… simply moving on to other treatment options.
Last year, Boehringer … frequent surveys of various doctors across specialties to analyze … suppurativa and uveitis. The drug is primarily used for stubborn … Remicade, J&J’s Simponi, Takeda’s Entyvio, Gilead …
-
Global Simponi And Simponi Aria Golimumab Market Insights 2025: Key Trends, Market Size, And Growth Forecast
19 Mar 2025 15:46 GMT
… treatments for arthritis and colitis.
o Ongoing clinical trials … disease treatment.
o Growth in subcutaneous drug delivery … Simponi and Simponi Aria Golimumab provide targeted biological treatment for … , a Germany-based pharmaceutical firm, announced an …
-
TALTZ’s Rapid Market Ascent Reflects its Unparalleled Ability to Transform the Treatment Landscape for Autoimmune Diseases | DelveInsight
24 Feb 2025 18:00 GMT
… Phase III clinical trials for psoriatic … the autoimmune treatment landscape @ TALTZ Medication Emerging … innovative Medicine’s TREMFYA and SIMPONI/SIMPONI ARIA, … , Janssen Biotech, Pozen, Novartis, Iroko Pharmaceuticals, Syntex Pharmaceuticals, Horizon …
-
EU Accepts for Regulatory Filing Proposed Biosimilar to Simponi®
10 Feb 2025 15:54 GMT
… a proposed biosimilar to Simponi® (golimumab), seeking a commercial … Union(EU). The reference medicine golimumab has been approved … in need of affordable treatments."
The MAA for … get special offers
from American Pharmaceutical Review – all delivered right …